{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-090045","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2026-08-04T10:47:58+00:00","discovered_at":"2026-08-04T10:50:00.342634+00:00","generated_at":"2026-08-04T10:50:14.042796+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merck Q2 2026: GAAP loss $0.54 on $16.6B sales; raises FY2026 guidance","bullets":["Total worldwide sales $16.6B, up 5% (4% ex-FX); KEYTRUDA/KEYTRUDA QLEX sales $8.4B (+5%).","GAAP loss per share $0.54; non-GAAP loss per share $0.13; both include $2.31/share charge for Terns acquisition.","Full-year 2026 guidance: sales range raised to $66.3B-$67.3B; non-GAAP EPS $2.66-$2.76 (includes $2.43/share Terns charge).","FDA approved LIPFENDRA (enlicitide), first once-daily oral PCSK9 inhibitor for hypercholesterolemia.","Completed acquisition of Terns for $6.8B; added MK-4208 (BCR::ABL1 inhibitor) to pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-090045","json":"https://secwatch.observer/filing/0001104659-26-090045.json","markdown":"https://secwatch.observer/filing/0001104659-26-090045.md","text":"https://secwatch.observer/filing/0001104659-26-090045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/0001104659-26-090045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T10:50:14.042796+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}